Bimonthly, Established in 1959
Open access journal


Ozempic (Semaglutide) Explained: A Psychologist’s Complete Guide to Weight-Loss, Brain Chemistry, and Mental-Health Impact

EDUCATIONAL ONLY — NOT MEDICAL ADVICE

Why Psychiatrists Are Talking about Ozempic for Weight-Loss and Mental Health

In recent years, psychiatrists and clinical psychologists have increasingly discussed the gut-brain connection and the role of metabolic regulation in mental health. Injectable GLP-1 receptor agonists such as semaglutide (marketed as Ozempic and Wegovy) have shown significant effects on appetite and weight, potentially changing the treatment of disorders associated with obesity, such as depression and anxiety disorders. Researches suggest that changes in metabolic signaling may affect neurotransmitter systems associated with reward and mood; this is of interest to psychiatrists because obesity and metabolic disorders are often associated with an increased risk of depression and anxiety [1], [2]. The discussion of Ozempic therefore extends beyond conventional endocrinology: psychiatrists, therapists, and patients themselves are keen to understand how effects on appetite and metabolism may correlate with changes in mood, eating behavior, and cognitive function.

GLP-1 is a gut hormone that crosses the blood-brain barrier and interacts directly with brain circuits. [3] The gut-brain connection is central to Ozempic’s psychological effects because when semaglutide enters the body, it mimics the food signal that travels to the brain via nerves and blood, telling the hypothalamus and reward centers that enough food has been consumed. This may reduce food cravings and change the way rewarding foods are experienced. Psychiatrists are already weighing the possibility of developing new treatments (semaglutide psychiatry) for patients whose eating disorders and mood symptoms are linked. For example, by curbing urges to overeat, the GLP-1 drug may help break the cycle where guilt from overeating worsens depression or anxiety. Ozempic’s gut-brain modulation is thus stimulating cross-disciplinary conversations: it is both an endocrinologist’s tool and a psychology paradigm linking metabolism to mood.

The emerging dialogue is deeply rooted in the science of gut-brain interactions. Researchers are increasingly recognizing that the gastrointestinal system is not merely a digestive apparatus but a source of neurological and hormonal signals that profoundly influence brain chemistry. In everyday clinical practice, the regular interplay between gastrointestinal hormones and central nervous system neurotransmitters is observed. We have prepared this comprehensive psych-informed overview of Ozempic for clinicians as well as educated patients.

How Semaglutide Works: GLP-1 Signals, Dopamine Reward Loops, and Appetite Control

To appreciate Ozempic’s multifaceted influence, it is important to fully understand the core pharmacological mechanism of its main ingredient, Semaglutide. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. The mechanism of its action involves stimulation of GLP-1 receptors located both in peripheral tissues (pancreas, gastrointestinal tract) and in the central nervous system. Activation of these receptors leads to increased insulin secretion at elevated glucose levels, slower gastric emptying, and decreased appetite due to the effect on satiety centers in the hypothalamus. From a neurochemical point of view, altered signals from the intestine can modulate dopaminergic reward pathways, reducing sensitivity to high-calorie foods and weakening the motivation to overeat. The neurocircuit can depict the effect of GLP-1 on the nuclei of the brain: signal from the gastrointestinal tract → nerve → nucleus of the solitary tract → hypothalamus and mesolimbic structures involved in reward. This mechanism underlies the effects of semaglutide on weight loss and possibly some mood regulation via metabolic and dopaminergic pathways.

GLP-1 neural signaling diagram
Fig. 1 Sequence diagram illustrating GLP-1 neural signaling and appetite suppression

A recent mouse study found that semaglutide reduced how much animals worked for sugary treats, yet paradoxically enhanced dopamine neuron firing when a reward was actually obtained [4]. This suggests semaglutide may decrease motivation but increase satisfaction of food. In humans, GLP-1 analogs like semaglutide blunt the brain’s anticipation of food (dampening insula activity to cues) while preserving or enhancing response when food is eaten. In plain terms, patients often crave food less intensely. One trial found people on semaglutide reported significantly reduced cravings for high-fat and sweet foods [5].

Finally, semaglutide slows digestion through slower gastric emptying. This physical bloating contributes to fullness and reduces snack frequency. The combined effect >powerfully suppresses appetite. Thus, semaglutide hijacks the GLP-1 weight-loss psychology: it makes the brain believe enough has been eaten (via hypothalamic satiety signals) and reduces the dopamine-driven urge to overeat (via reward modulation). The figure above illustrates this gut-brain interplay.

Gut-brain axis diagram
Fig. 2. Gut-brain axis

FDA-Approved Uses and Off-Label Benefits: Diabetes, Obesity, and Binge-Eating Disorder

Semaglutide, brand name Ozempic, was originally approved by the FDA for the treatment of type 2 diabetes, and a higher dose of semaglutide, brand name Wegovy, was approved by the FDA as a prescription drug for weight management in clinical obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition [6]. Large clinical trials followed, showing ~15% average body-weight reduction at one year on semaglutide, far exceeding most diet pills. In practice, clinicians use Ozempic or Wegovy to help patients achieve significant weight loss and related benefits (blood pressure, lipids, glycemia).

Off-label, the effects of semaglutide on eating behavior have spurred interest in its use for treating binge-eating disorder (BED). While semaglutide is not yet FDA-approved for BED, early studies are promising. For example, small trials and cohort studies have found that GLP-1RAs (mostly liraglutide, but analogous effects expected with semaglutide) markedly reduce binge episodes and binge-related weight gain. [5] Patients report fewer urges and fewer loss-of-control eating events while on therapy. One review concluded that liraglutide and dulaglutide produced clinically meaningful reductions in binge frequency, weight, and psychiatric symptoms. [7] Larger RCTs are still needed, but some clinicians already consider semaglutide for patients with obesity + BED, especially when first-line CBT has failed.

Semaglutide has also been explored in type 1 diabetes, where it showed less effect on glycemia, and pre-diabetes, where it reduces progression to diabetes. The results of tests of other GLP-1 analogs have been not so impressive.

By the way, although some people take Ozempic without prescription for “cosmetic” weight loss, that means, without clinical obesity, psychiatrists must take into consideration the overlap with disordered eating. Using Ozempic in a patient with underlying bulimia or night-eating syndrome, for instance, requires caution and often coordination with therapy.

Depression, Anxiety, and Food Cravings: The Psychiatric Comorbidities Ozempic May Influence

Depression

Patients with obesity frequently experience depressive symptoms, and vice versa. The data on semaglutide’s effect on mood are mixed but generally reassuring. A systematic review and meta-analysis of available trials shows that, on average, semaglutide modestly improved depression scores compared to placebo [8]. Similarly, a pooled post-hoc analysis of the STEP trials (overweight adults without major psychiatric history) showed no increase in depression or suicidal ideation. On the contrary, there was a small statistically significant drop in depression scale scores [2]. However, a large retrospective cohort study reported that patients on GLP-1RAs had nearly double the risk of developing any psychiatric disorder (and specifically ~2–3 times the risk of diagnosed depression or suicidal behavior) compared to control group [9]. At the same time, another recent real-world study found no increased 12-month risk of psychiatric events on semaglutide; it even saw lower risks of cognitive problems and smoking misuse [10].

It can be underlined that psychiatrists should monitor the patient’s mood closely. If a patient with a history of major depression starts treatment with semaglutide, we counsel vigilance. Many patients do feel uplifted by significant weight loss (improved self-esteem, energy, control), but some report mood dips — especially if GI side effects or dietary change (low calories) trigger irritability.

Anxiety

Currently, the data on anxiety specifically are sparse. Since obesity and anxiety often coexist, some wonder if reducing weight and improving metabolism might alleviate anxiety symptoms. So far, no clinical trial have tested semaglutide as an anti-anxiety treatment. One observational study found higher rates of anxiety diagnoses among GLP-1RA users [9], mirroring its findings on depression. But again, confounding (sicker or more stressed patients getting therapy) could explain this. On the other hand, the psychiatric outcomes study found no overall increase in anxiety events after semaglutide [10]. Given the lack of clear evidence, we can say semaglutide likely has minimal direct effect on anxiety biology. Most changes are secondary to weight loss or treatment side effects (e.g. if nausea triggers anxiety). Clinicians should continue standard anxiety screening and treatment, integrating any weight-loss drug as part of a comprehensive treatment plan.

Food Cravings

Perhaps the most dramatic psychiatric impact of Ozempic is on food cravings and binge eating. By altering brain reward signals, semaglutide tends to blunt the compulsive hunger that drives binge eating. Patients often report that “food just doesn’t taste as good, and the urge to snack is gone” on GLP-1 therapy. This is supported by imaging studies: GLP-1RAs decrease the brain’s anticipatory response to palatable foods (especially in the insula and striatum) [3].

Clinically, this manifests as fewer cravings and sometimes reduced binge frequency. One systematic review noted that even though robust RCTs are lacking, the existing cases and small studies suggest GLP-1RAs “reduce binge-eating frequency and improve comorbidities”. Real-world data hint that patients with bulimia or night-eating syndrome see benefits, especially when the medication is combined with therapy. In short, while Ozempic is not a magic cure for the psychological reasons of BED, its appetite-resetting effects can substantially ease the vicious cycle of cravings.

Combining Ozempic with CBT and DBT: Evidence-Based Behavioral Strategies for Lasting Results

Psychotherapeutic approaches, especially cognitive behavioral therapy (CBT) and dialectical behavioral therapy (DBT), have proven to be effective in treating eating disorders, depression, and anxiety disorders [11]. More than that, behavioral therapy remains the cornerstone of treating obesity, even in the GLP-1 era. Integrating psychotherapeutic approaches with semaglutide can be synergistic. For example, GLP-1-induced satiety makes it easier for patients to stick to meal plans created in CBT, and therapy skills can handle any discomfort from dietary change or GI side effects. For today, integrated approach is the most promising one. In a recent real-world study of diabetics, patients starting GLP-1RAs who also participated in a structured CBT program lost significantly more weight (average 8.5% body weight) than those on medication with only basic nutrition counseling (6.3%) or standard care (3.1%) [12]. In addition, the behavioral component maintains the weight loss for a longer period. We can explain this by that fact that semaglutide may give patients the initial momentum in form of fast early weight drop which enhances motivation for long-term lifestyle change.

In practice, a psychologist or dietitian works on portion control, regular meal times, and strategies to cope with cravings while semaglutide reduces hunger. For example, if a patient learns to overcome urges to binge through relaxation techniques in DBT, they may need to use these skills less often while taking Ozempic — effectively “retraining” their brain to experience satisfaction from food more quickly than before.

During treatment, it is important not to encourage patients to view semaglutide as a quick fix. CBT can reframe Ozempic as a tool rather than a lifeline, emphasizing the need to develop sustainable healthy habits. Furthermore, a psychotherapeutic approach can help manage and mitigate “moral” side effects. If a patient becomes fixated on cutting calories to maximize weight loss, it may make sense to intervene with cognitive therapy. Overall, the best results are achieved when behavioral interventions and GLP-1 inhibitors are seen as partners: research confirms that structured programs (including exercise coaching and cognitive behavioral therapy) combined with Ozempic result in more patients achieving measurable weight loss and better mental health outcomes than with medication alone.

Side Effects through a Psychological Lens: Nausea, Mood Shifts, and Rare Suicidal Thoughts

Side effects of semaglutide often include gastrointestinal discomfort: nausea, vomiting, constipation, which can negatively affect the quality of life and emotional state of the patient [2]. Chronic nausea can increase anxiety and irritability, especially at the beginning of therapy. It is important to provide patients with support: recommendations for eating small portions, adequate hydration, gradual schemes for increasing the dosage of the drug, which helps to reduce the manifestation of unpleasant symptoms. Rare but serious cases of suicidal thoughts have been described in post-marketing reports and individual clinical observations [13]. Although the causal relationship is not always confirmed, patients with a history of severe depressive disorders require more careful monitoring. Psychiatrists are advised to regularly assess the mood of patients, especially in the first months of treatment. If severe depression or suicidal thoughts occur, the possibility of stopping therapy or prescribing compensatory psychopharmacotherapy and psychotherapy should be considered. At the same time, some patients may experience improved mood associated with increased self-esteem after weight loss, as reported by sources such as [14].

If a patient complains of persistent hopelessness or intrusive negative thoughts after starting Ozempic, we must evaluate medication versus underlying depression. Most experts emphasize that active suicidal ideation is not a known pharmacological effect of GLP-1 RAs [2].

In general, from a psychological perspective, Ozempic’s side effects are mainly about physical discomfort affecting mental state, not new psychiatric syndromes. We advise patients and families about nausea (the most common trigger of distress) and ensure they have resources (anti-emetics, therapy support). We also encourage open communication: if the patient starts feeling worse, let the doctor know about it. This collaborative, non-blaming approach prevents stigma and catches rare problems early.

Ethical and Equity Concerns: Cost, Access, and Weight-Stigma in the Ozempic Era

Ozempic and other GLP-1 agonists are expensive, creating barriers to access for socially disadvantaged groups. [15] Stratified access to these drugs may exacerbate health inequalities: those who can afford the therapy benefit from improved metabolic and possibly mental health, while others are left without effective tools. In addition, the stigma of obesity is increasing in society: the emergence of “quick-acting” drugs raises questions about “easy ways” and “cheating” in losing weight. [16] Psychologists and psychiatrists play a key role in breaking down these stereotypes: it is important to focus on a holistic approach to health, recognizing the influence of biological factors, and combating weight stigma. Ethical dilemmas are also associated with off-label use: patients may seek drugs to correct eating behavior without strict clinical indications, which carries risks of inappropriate use and side effects. Patients should be informed about unofficial indications, emphasizing the lack of a complete evidence base and the need for medical supervision.

There’s hope that effective medications will reduce stigma by framing obesity as a treatable medical condition. Indeed, experts point out that GLP-1 drugs can help shift public perception: obesity is a complex biology issue, not just willpower. [17] However, stigma can also get worse in two ways. First, people who can’t afford or access Ozempic may feel judged for “not trying hard enough” while others take a “magic shot.” The narrative of a “miracle weight drug” can inadvertently blame those without it. Second, some individuals on these drugs feel judged as taking an “easy way out” of weight loss — a stigma similar to what bariatric surgery patients face. Recent reviews note that while GLP-1 therapies have great potential, disparities in cost and stigma must be addressed to prevent creating two classes of treatment: one for the affluent and one for the marginalized.

Psychologically, we must be vigilant not to frame weight as a moral failing. Our role includes advocating for fair insurance coverage and educating colleagues to treat medication-assisted weight loss the way we treat other chronic conditions. Reducing shame around using Ozempic (just as we reduced it around insulin or antidepressants) is part of psychiatric care.

Case Study: Treating Binge-Eating and Atypical Depression with Semaglutide and Therapy

Below we present a clinical example (anonymized and generalized). Emily, a 35-year-old woman, BMI 32 kg/m², long-term history of binge eating disorder (BED) and subsyndromal atypical depression: depressed mood, decreased energy, increased appetite in response to stress, guilt after overeating. Previously underwent CBT courses without a sustainable effect: binge eating episodes resumed with new stress.

Assessment and Plan

Recognizing the interplay of Emily’s mood, weight, and eating, we designed an integrated treatment. We started semaglutide 0.25 mg weekly (eventually increasing to 2.4 mg) to target her obesity and food cravings. We also intensified therapy: switching from general CBT to a specialized CBT for BED plus some DBT techniques for emotion regulation. She met biweekly with her therapist to develop coping skills for stress eating and to challenge negative self-talk around body image.

Course

In the first month of treatment with semaglutide, Emily experienced moderate nausea. With supportive guidance (small bland meals, ginger tea, mindfulness exercises), the nausea abated. Interestingly, by week 8 she reported fewer binge urges. Foods she used to crave (ice cream, chips) lost their attractiveness, and she often felt satiated on normal portions. Her therapist noted a decrease in anxiety before meal situations. By 3 months, Emily had lost 10% of her body weight. Her depression score dropped from moderate to mild. She and her therapist attributed this partly to feeling more energetic with weight loss, and partly to success in reducing binges. They worked together to reinforce healthy routines: she kept a daily eating journal (CBT strategy) and practiced “urge surfing” when a craving hit (DBT strategy).

Outcome

Over 6 months, Emily’s binges went from 2 per week to about 1-2 per month. Her atypical depressive symptoms improved noticeably: her mood became brighter, sleep normalized, and she started exercising regularly. She reported feeling more in control of her eating without spiraling into self-blame. This case illustrates how combining Ozempic with psychotherapy can yield synergistic benefits. Semaglutide quickly reduced biological urges and jump-started weight loss, while CBT and DBT provided coping tools and addressed underlying cognitive patterns. Emily’s success is consistent with studies showing that GLP-1RAs reduce binge behavior and improve mood [7].

Quick-Reference Checklist for Clinicians Considering Ozempic

  • Patient Selection: Confirm obesity/overweight status and relevant comorbidities (diabetes, hypertension). Screen for eating disorders and psychiatric history. Ozempic is FDA-approved for BMI ≥30, or ≥27 in case of comorbidity, but may be considered off-label in carefully selected BED cases.
  • Contraindications: Check for personal or family history of medullary thyroid carcinoma or MEN2. Avoid in pregnancy/breastfeeding. Use caution in case of history of pancreatitis.
  • Initiation and Dosing: Start at low dose (0.25 mg weekly) and increase slowly to minimize nausea. Educate patient on injection technique and dose schedule.
  • Adjunctive Therapy: Always pair with lifestyle support. Refer to a dietitian or psychologist for behavioral programs (e.g. CBT for weight management or BED. Emphasize nutritional adequacy to avoid deficits (especially since appetite will drop).
  • Monitor Side Effects: Instruct patient on managing GI side effects (small meals, ginger, hydration). Schedule follow-up to assess tolerance. Reduce dose temporarily if needed.
  • Mental Health Monitoring: Monitor mood and suicidal ideation as with any chronic medication change. Educate patient/family to report any severe mood changes. Remember: clinical trials haven’t shown increased suicidality, but vigilance is prudent.
  • Weight-Stigma Awareness: Use stigma-free language. Reinforce that obesity is a medical condition. Be aware of any shame the patient might feel about using a “weight drug,” and address it positively.
  • Cost Planning: Verify coverage early. If coverage is denied, discuss options (patient assistance programs, or alternative therapies). Avoid delaying therapy due to cost barriers.
  • Integration with Psychiatry and Psychotherapy: Coordinate care with mental health providers. Cognitive/behavioral strategies are crucial for managing eating behaviors and emotions. Remind that GLP-1 is an adjunct, not a sole solution.
  • Set Realistic Expectations: Counsel patients on expected rate of weight loss (often slower than society hype). Review that maximal satiety effects occur after a few weeks. Emphasize that if weight loss stalls, this is common and signals need to fine-tune diet and therapy, not to give up.
  • Long-Term Planning: Discuss duration of therapy (ongoing versus trial period). Plan for maintenance strategy and discuss potential rebound weight gain if medication stops. Encourage sustained behavioral changes.

Next Up: Safe Ways to Buy Ozempic Online — Stay Tuned

In the next article, we will take a detailed look at legal and safe ways to purchase semaglutide through telemedicine and official channels, as well as the risks of buying illegal or counterfeit drugs. Stay tuned for detailed recommendations and practical steps. We will cover how to identify legitimate online pharmacies, avoid counterfeit or dangerous sources, and understand shipping and handling concerns. – How to Buy Ozempic Online Safely: A Psychologist’s Checklist for Patients and Clinicians

Compliance

Ozempic (semaglutide) opens up new horizons for both metabolic therapy and a multidisciplinary approach to mental health in patients with obesity and eating disorders. On the one hand, powerful appetite suppression and the potential to improve metabolic parameters may contribute to improved mood and well-being. On the other hand, it is necessary to carefully monitor the risk of unwanted mental effects and provide comprehensive support through psychotherapy and multidisciplinary interaction of doctors. Psychiatrists and clinical psychologists should play an active role in integrating these drugs into clinical practice, helping patients make informed decisions and achieve lasting results without compromising mental health.

Our following material will tell you how to safely and legally purchase Ozempic online, minimizing the risks of counterfeiting and improper use.

Academic editors (peer reviewers)

  • Chunbo Li, MD PhD (李春波) —Shanghai Jiao Tong University, Shanghai, China
  • Changyong Feng, PhD — Department of Biostatistics and Computational Biology,
    University of Rochester Medical Center    , Rochester NY, USA
  • Hua He, PhD (贺华) —University of Rochester, New York NY, USA
  • Xin M. Tu, PhD (屠心铭) —University of Rochester, New York NY, USA

Bibliography

  1. Loh JS, Mak WQ, Tan LKS, Ng CX, Chan HH, Yeow SH, Foo JB, Ong YS, How CW, Khaw KY. Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transduct Target Ther. 2024 Feb 16;9(1):37. doi: 10.1038/s41392-024-01743-1. PMID: 38360862; PMCID: PMC10869798. Web: https://pubmed.ncbi.nlm.nih.gov/38360862/
  2. Wadden TA, Brown GK, Egebjerg C, et al. Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials. JAMA Intern Med. 2024;184(11):1290–1300. doi:10.1001/jamainternmed.2024.4346 Web: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2823084
  3. Eren-Yazicioglu CY, Yigit A, Dogruoz RE, Yapici-Eser H. Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review Analysis of Studies on Palatable Food, Drugs of Abuse, and Alcohol. Front Behav Neurosci. 2021 Jan 18;14:614884. doi: 10.3389/fnbeh.2020.614884. PMID: 33536884; PMCID: PMC7848227. Web: https://pmc.ncbi.nlm.nih.gov/articles/PMC7848227/
  4. Kooij K. L. et al. GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling // Neuroscience Applied. 2024. Vol. 3. p. 103925. Web: https://www.sciencedirect.com/science/article/pii/S2772408523029071
  5. Bettadapura, S., Dowling, K., Jablon, K. et al. Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities. Int J Obes 49, 418–426 (2025). https://doi.org/10.1038/s41366-024-01500-y. Web: https://www.nature.com/articles/s41366-024-01500-y
  6. Breit S, Hubl D. The effect of GLP-1RAs on mental health and psychotropics-induced metabolic disorders: A systematic review. Psychoneuroendocrinology. 2025 Jun;176:107415. doi: 10.1016/j.psyneuen.2025.107415. Epub 2025 Mar 20. PMID: 40138849. Web: https://pubmed.ncbi.nlm.nih.gov/40138849/
  7. Aoun L, Almardini S, Saliba F, Haddadin F, Mourad O, Jdaidani J, Morcos Z, Al Saidi I, Bou Sanayeh E, Saliba S, Almardini M, Zaidan J. GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review. J Clin Transl Endocrinol. 2024 Feb 29;35:100333. doi: 10.1016/j.jcte.2024.100333. PMID: 38449772; PMCID: PMC10915596. Web: https://pmc.ncbi.nlm.nih.gov/articles/PMC10915596/
  8. Chen X, Zhao P, Wang W, Guo L, Pan Q. The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis. Am J Geriatr Psychiatry. 2024 Jan;32(1):117-127. doi: 10.1016/j.jagp.2023.08.010. Epub 2023 Aug 21. PMID: 37684186. Web: https://pubmed.ncbi.nlm.nih.gov/37684186/
  9. Kornelius, E., Huang, JY., Lo, SC. et al. The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy. Sci Rep 14, 24433 (2024). https://doi.org/10.1038/s41598-024-75965-2 Web: https://www.nature.com/articles/s41598-024-75965-2
  10. De Giorgi R, Koychev I, Adler AI, Cowen PJ, Harmer CJ, Harrison PJ, Taquet M. 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study. EClinicalMedicine. 2024 Jul 10;74:102726. doi: 10.1016/j.eclinm.2024.102726. PMID: 39764175; PMCID: PMC11701436. Web: https://pubmed.ncbi.nlm.nih.gov/39764175
  11. Bartel S, McElroy SL, Levangie D, Keshen A. Use of glucagon‐like peptide‐1 receptor agonists in eating disorder populations. Intl J Eating Disorders. 2024;57(2):286-293. doi:10.1002/eat.24109 Web: https://onlinelibrary.wiley.com/doi/10.1002/eat.24109
  12. Petroni ML, Montesi L, Colosimo S, Caletti MT, Mazzotti A, Marchesini G. Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study. Endocrinol Diabetes Metab. 2019 Jul 26;2(4):e00082. doi: 10.1002/edm2.82. PMID: 31592154; PMCID: PMC6775466. https://pubmed.ncbi.nlm.nih.gov/31592154
  13. Li JR, Cao J, Wei J, Geng W. Case Report: Semaglutide-associated depression: a report of two cases. Front Psychiatry. 2023 Aug 29;14:1238353. doi: 10.3389/fpsyt.2023.1238353. PMID: 37706035; PMCID: PMC10495976. Web: https://pmc.ncbi.nlm.nih.gov/articles/PMC10495976
  14. Breit S, Hubl D. The effect of GLP-1RAs on mental health and psychotropics-induced metabolic disorders: A systematic review. Psychoneuroendocrinology. 2025 Jun;176:107415. doi: 10.1016/j.psyneuen.2025.107415. Epub 2025 Mar 20. PMID: 40138849. Web: https://pubmed.ncbi.nlm.nih.gov/40138849/
  15. https://www.verywellhealth.com/glp-1s-and-mental-health-11738241
  16. https://nypost.com/2025/05/17/health/weight-loss-diabetes-drugs-can-cause-mood-changes-what-to-know-about-behavioral-side-effects
  17. Heitmann BL. The Impact of Novel Medications for Obesity on Weight Stigma and Societal Attitudes: A Narrative Review. Curr Obes Rep. 2025 Feb 5;14(1):18. doi: 10.1007/s13679-025-00611-5. PMID: 39907856; PMCID: PMC11799028. Web: https://pubmed.ncbi.nlm.nih.gov/39907856